Vetter and Rentschler Biopharma have announced joining forces to boost their services and along the biopharmaceutical value chain.
Behind this decision was the conclusion about the drug development growing increasingly complex and cost-intensive, which in turn puts biopharmaceutical companies under a lot of pressure to streamline their products’ path to market.
“Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before,” said Prof. Dr. Nikolaus F. Rentschler, Chairman of the Board of Rentschler Biopharma.
Over the next months, these opportunities will be further validated in pilot client projects with joint teams from both companies.
Peter Soelkner, Managing Director of Vetter said: “There are important synergies between our business portfolios that will provide valuable market foresight that can positively impact our clients’ business and patients’ treatment. Combining our experience enables us to deliver new efficiencies and pathways that streamline the development and the supply chain in ways that address the challenges of complexity companies across the industry are facing.”
Both companies will continue to independently address and service current and new clients as they explore opportunities for cooperative integration of approaches to complex molecules in todays’ rapidly evolving global healthcare environment, it was said in the Rentschler Biopharma SE’s press release.